1 year return (CAGR)
-13.45%
Arbonia AG Exchange (SW, CHF)
ARBN.SW
4.99
+0.49 (+11.26%)
IndustrialsBuilding Products & Equipment
Loading...
3 year return (CAGR)
-18.58%
5 year return (CAGR)
-23.98%
10 year return (CAGR)
-11.23%
Computer Modeling Group 2027 Q1 - Turnarounds seldom turn?
Read MoreMarketcap
339.72M
Price/Sales
0.28
Ent value
707.98M
Price/Book
0.47
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
-255.97%
Trailing P/E
3.74
PEG
-
Forward P/E
29.51
EPS growth
-
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 4.82 |
| Daily high | 5.18 |
| Daily low | 4.80 |
| Daily Volume | 782K |
| All-time high | 92.34 |
| 1y analyst estimate | 4.75 |
| Beta | 0.76 |
| EPS (TTM) | 1.31 |
| Dividend per share | 0.00 |
| Ex-div date | 29 Apr 2025 |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ARBN.SW | S&P500 | |
| Current price drop from All-time high | -94.60% | -1.99% |
| Highest price drop | -96.19% | -56.47% |
| Date of highest drop | 8 Jul 2026 | 9 Mar 2009 |
| Avg drop from high | -65.67% | -10.69% |
| Avg time to new high | 110 days | 12 days |
| Max time to new high | 4846 days | 1805 days |
News
A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
September 15, 2026
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
September 15, 2026
Ingrid Zhang, an accomplished global biopharmaceutical leader, joins Legend Biotech following a comprehensive Board-led search processBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biote...
September 15, 2026
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
September 14, 2026
The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The tre...
September 14, 2026
AstraZeneca's Etcamah fails to improve PFS significantly in a phase III first-line breast cancer study, while its approved use remains unaffected.
September 14, 2026
Palantir Technologies' (PLTR) AIPCon 11 highlighted growing demand for data sovereignty, with custom
September 14, 2026
Press release - Regulated Information Melexis: update on the share buy-back program Ieper, Belgium – 14 September 2026, 17.45 hrs CET Melexis reports the purchase of 3,408 Melexis shares on Euronext B...
September 14, 2026
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
September 14, 2026